TABLE 3.
Pediatric malignancy | Contemporary frontline therapeutic modalities* |
Potential late effects† |
---|---|---|
Acute lymphoblastic leukemia & Non-Hodgkin lymphoma |
Glucocorticoids Vinca alkaloids Antimetabolites Anthracyclines Alkylating agents |
Bone mineral density deficits Peripheral and/or sensory neuropathy Cognitive deficits Cardiomyopathy Gonadal dysfunction/infertility |
Acute myeloid leukemia | Anthracyclines Antimetabolites Epipodophyllotoxins |
Cardiomyopathy |
Ewing sarcoma | Surgical resection Epipodophyllotoxins Alkylating Agents Anthracyclines Vinca alkaloids Primary/metastatic site irradiation |
Functional deficits Secondary leukemia Gonadal dysfunction/infertility Cardiomyopathy Peripheral and/or sensory neuropathy Subsequent neoplasms |
Hodgkin lymphoma | Glucocorticoids Vinca alkaloids Anthracyclines Alkylating agents Involved node radiation |
Bone mineral density deficits Peripheral and/or sensory neuropathy Cardiomyopathy Pulmonary fibrosis Gonadal dysfunction/infertility Hypothyroidism Subsequent neoplasms |
Medulloblastoma | Surgical resection Vinca alkaloids Alkylating agents Heavy metals Craniospinal irradiation |
Neurologic deficits Peripheral and/or sensory neuropathy Neuroendocrine dysfunction Gonadal dysfunction/infertility Hearing loss Renal dysfunction Cognitive deficits Vasculopathy/stroke |
Neuroblastoma | Surgical resection Epipodophyllotoxins Alkylating agents Anthracyclines Heavy metals Immunotherapy |
Secondary leukemia Gonadal dysfunction/infertility Hearing loss Renal toxicity Cardiomyopathy Subsequent neoplasms |
Osteosarcoma | Surgical resection Antimetabolites Alkylating agents Heavy metals |
Functional deficits Renal dysfunction Gonadal dysfunction/infertility Cardiomyopathy Hearing loss |
Rhabdomyosarcoma | Surgical resection Vinca alkaloids Anthracyclines Involved site radiation |
Peripheral and/or sensory neuropathy Cardiomyopathy Subsequent neoplasms |
Wilms tumor | Nephrectomy Vinca alkaloids Anthracyclines Primary/metastatic site irradiation |
Renal dysfunction Kyphoscoliosis Peripheral and/or sensory neuropathy Gonadal dysfunction/infertility Cardiomyopathy Subsequent neoplasms |
Exposures listed may vary as therapy is stratified based on clinical and pathological features of pediatric malignancy and early response to therapy.
The risk of specific late effects varies in magnitude based on specific agents and modalities and dose; survivors with favorable and responsive malignancies may have substantially lower risks for specific late effects due to limited exposures of the agents and modalities listed.